329 related articles for article (PubMed ID: 37627900)
1. Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer.
Chin FW; Chan SC; Veerakumarasivam A
Diagnostics (Basel); 2023 Aug; 13(16):. PubMed ID: 37627900
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer.
Dong B; Liang J; Li D; Song W; Song J; Zhu M; Zhao S; Ma Y; Yang T
Front Mol Biosci; 2021; 8():688298. PubMed ID: 34368227
[No Abstract] [Full Text] [Related]
3. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
[TBL] [Abstract][Full Text] [Related]
5. [Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer].
Wang F; Qin CP; DU YQ; Liu SJ; Li Q; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):669-673. PubMed ID: 35950390
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Heer R; Lewis R; Duncan A; Penegar S; Vadiveloo T; Clark E; Yu G; Mariappan P; Cresswell J; McGrath J; N'Dow J; Nabi G; Mostafid H; Kelly J; Ramsay C; Lazarowicz H; Allan A; Breckons M; Campbell K; Campbell L; Feber A; McDonald A; Norrie J; Orozco-Leal G; Rice S; Tandogdu Z; Taylor E; Wilson L; Vale L; MacLennan G; Hall E
Health Technol Assess; 2022 Oct; 26(40):1-144. PubMed ID: 36300825
[TBL] [Abstract][Full Text] [Related]
7. Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?
Sapre N; Anderson PD; Costello AJ; Hovens CM; Corcoran NM
Urol Oncol; 2014 Jan; 32(1):48.e9-17. PubMed ID: 24140246
[TBL] [Abstract][Full Text] [Related]
8. Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression.
Chin FW; Hussin H; Chau DM; Ong TA; Yunus R; Abdul Razack AH; Yusoff K; Chan SC; Veerakumarasivam A
Diagnostics (Basel); 2023 Aug; 13(16):. PubMed ID: 37627895
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated expression of homebox gene HOXA13 is correlated with the poor prognosis in bladder cancer.
Hu H; Chen Y; Cheng S; Li G; Zhang Z
Wien Klin Wochenschr; 2017 Jun; 129(11-12):391-397. PubMed ID: 27830363
[TBL] [Abstract][Full Text] [Related]
10. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.
Rouprêt M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Longo F; Montanari E; Palou J; Sylvester RJ
Eur Urol Focus; 2022 Nov; 8(6):1643-1649. PubMed ID: 35300937
[TBL] [Abstract][Full Text] [Related]
11. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review.
Casadevall D; Kilian AY; Bellmunt J
Cancer Treat Rev; 2017 Dec; 61():82-93. PubMed ID: 29121502
[TBL] [Abstract][Full Text] [Related]
13. Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance.
Lee N; Canagasingham A; Bajaj M; Shanmugasundaram R; Hutton A; Bucci J; Graham P; Thompson J; Ni J
Front Oncol; 2022; 12():1019391. PubMed ID: 36203422
[TBL] [Abstract][Full Text] [Related]
14. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
[TBL] [Abstract][Full Text] [Related]
15. Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer.
Mutlu N; Turkeri L; Emerk K
Clin Chem Lab Med; 2003 Aug; 41(8):1069-74. PubMed ID: 12964816
[TBL] [Abstract][Full Text] [Related]
16. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
Karaoglu I; van der Heijden AG; Witjes JA
World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
[TBL] [Abstract][Full Text] [Related]
17. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
Tan WS; Feber A; Dong L; Sarpong R; Rezaee S; Rodney S; Khetrapal P; de Winter P; Ocampo F; Jalil R; Williams NR; Brew-Graves C; Kelly JD
BMC Cancer; 2017 Nov; 17(1):767. PubMed ID: 29141603
[TBL] [Abstract][Full Text] [Related]
18. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.
Shariat SF; Savage C; Chromecki TF; Sun M; Scherr DS; Lee RK; Lughezzani G; Remzi M; Marberger MJ; Karakiewicz PI; Vickers AJ
Cancer; 2011 Jul; 117(13):2892-7. PubMed ID: 21692050
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis.
Andrew AS; Karagas MR; Schroeck FR; Marsit CJ; Schned AR; Pettus JR; Armstrong DA; Seigne JD
Cancer Epidemiol Biomarkers Prev; 2019 Apr; 28(4):782-788. PubMed ID: 30700445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
